Frovatriptan is Effective and Well Tolerated in Korean Migraineurs: A Double-Blind, Randomized, Placebo-Controlled Trial
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose Frovatriptan is a selective 5-HT1B/1D agonist with a long duration of action and a low incidence of side effects. Although several placebo-controlled trials have documented the clinical efficacy and safety of frovatriptan in adults with migraine, this drug has not previously been studied in Asian including Korean patients. Methods In this double-blind multicenter trial, 229 patients with migraine were randomized to receive frovatriptan 2.5 mg or placebo upon the occurrence of a moderate-to-severe migraine. The primary outcome was the 2-hour headache response rate. Results Frovatriptan significantly increased the 2-hour headache response rate compared with placebo (52.9% vs. 34.0%, p=0.004). The headache response rates at 4, 6, and 12 hours were significantly higher in the frovatriptan group than in the placebo group, as was the pain-free rate at 2hours (19.0% vs. 5.7%, p=0.004), 4 hours (40.7% vs. 23.0%, p=0.006), and 6 hours (56.1% vs. 34.0%,p=0.002). The median time to a headache response was significantly shorter in the frovatriptan group than in the placebo group (2.00 hours vs. 3.50 hours, p<0.001). The use of rescue medications was more common in the placebo group (p=0.005). Chest tightness associated with triptan was infrequent (2.5%), mild, and transient. Conclusions These results demonstrate that 2.5-mg frovatriptan is effective and well tolerated in Korean migraineurs for acute treatment of migraine attacks.
Abstract
Background and Purpose Frovatriptan is a selective 5-HT1B/1D agonist with a long duration of action and a low incidence of side effects. Although several placebo-controlled trials have documented the clinical efficacy and safety of frovatriptan in adults with migraine, this drug has not previously been studied in Asian including Korean patients. Methods In this double-blind multicenter trial, 229 patients with migraine were randomized to receive frovatriptan 2.5 mg or placebo upon the occurrence of a moderate-to-severe migraine. The primary outcome was the 2-hour headache response rate. Results Frovatriptan significantly increased the 2-hour headache response rate compared with placebo (52.9% vs. 34.0%, p=0.004). The headache response rates at 4, 6, and 12 hours were significantly higher in the frovatriptan group than in the placebo group, as was the pain-free rate at 2hours (19.0% vs. 5.7%, p=0.004), 4 hours (40.7% vs. 23.0%, p=0.006), and 6 hours (56.1% vs. 34.0%,p=0.002). The median time to a headache response was significantly shorter in the frovatriptan group than in the placebo group (2.00 hours vs. 3.50 hours, p<0.001). The use of rescue medications was more common in the placebo group (p=0.005). Chest tightness associated with triptan was infrequent (2.5%), mild, and transient. Conclusions These results demonstrate that 2.5-mg frovatriptan is effective and well tolerated in Korean migraineurs for acute treatment of migraine attacks.
참고문헌 (23)
- Ferrari MD, "On serotonin and migraine:a clinical and pharmacological review", Cephalalgia, 13, pp.151~165 (1993)
- Tfelt-Hansen P, "Triptans in migraine:a comparative review of pharmacology,pharmacokinetics and efficacy", Drugs, 60, pp.1259~1287 (2000)
- Brown AM, "SB 209509 (VML 251), a potent constrictor of rabbit basilar artery with high affinity and selectivity for human 5-HT1D receptors", Br J Pharmacol, 119, pp.110P~ (1996)
- Goldstein J, "Frovatriptan for the acute treatment of migraine:a dose-finding study", Headache, 42, pp.41~48 (2002)
- 강나미, "Screening of the A11084G Polymorphism and Scanning of a Mitochondrial Genome SNP in Korean Migraineurs", Journal of Clinical Neurology, 3(3), pp.127~132 (2007), 대한신경과학회
- Sakai F, "Zolmitriptan is effective and well tolerated in Japanese patients with migraine:a dose-response study", Cephalalgia, 22, pp.376~383 (2002)
- Sakai F, "Eletriptan for the acute treatment of migraine:results of bridging a Japanese study to Western clinical trials", Curr Med Res Opin, 20, pp.269~277 (2004)
- Shimazawa R, "Development of triptans in Japan:bridging strategy based on the ICH-E5 guideline", J Health Sci, 52, pp.443~449 (2006)
- Yates RA, "The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects", Eur J Clin Pharmacol, 58, pp.247~252 (2002)
- Rapoport A, "Dose range-finding studies with frovatriptan in the acute treatment of migraine", Headache, 42, pp.S74~S83 (2002)
- Ryan R, "Clinical efficacy of frovatriptan: placebo-controlled studies", Headache, 42(Suppl,2), pp.S84~S92 (2002)
- Silberstein SD, "A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine", Neurology, 63, pp.261~269 (2004)
- "Headache Classification Committee of the International Headache Society.The International Classification of Headache Disorders,2nd edition", Cephalalgia 24 Suppl, 1, pp.1~160 (2004)
- Protocol No, "251", 96, Vernalis, pp.2002, ~
- Lee SB, "Double-blind placebo-controlled randomized clinical trial of zolmitriptan in acute treatment of migraine", J Korean Neurol Assoc, 19, pp.29~35 (2001)
- Havanka H, "Efficacy of naratriptan tablets in the acute treatment of migraine:a dose-ranging study.Naratriptan S2WB2004 Study Group", Clin Ther, 22, pp.970~980 (2000)
- Ferrari MD, "Oral triptans(serotonin 5-HT(1B", 1D)agonists)in acute migraine treatment:a meta-analysis of 53 trials, 2001, pp.358, 1668~1675
- Jo KD, "Oral sumatriptan for acute treatment of migraine A single-blind placebo-controlled study", J Korean Neurol Assoc, 13, pp.77~83 (1995)
- Noh YW, "A double-blinded,placebo-controlled,multicenter cross-over study of 2.5mg naratriptan in acute migraineurs", Korean J Headache, 2, pp.53~60 (2001)
- Pfaffenrath V, "Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan", Headache, 38, pp.184~190 (1998)
- Rapoport AM, "Optimizing the dose of zolmitriptan(Zomig,311C 90)for the acute treatment of migraine.A multicenter,double-blind,placebo-controlled,dose range-finding study.The 017 Clinical Trial Study Group", Neurology, 49, pp.1210~1218 (1997)
- Dahlof C, "Safety and tolerability of the novel 5-HT 1B", 1D agonist rizatriptan in migraineurs, 1999, pp.(Suppl 1), S16~S18
- Wang SJ, "Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine", J Chin Med Assoc, 70, pp.39~46 (2007)